Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials
The chief therapeutic goal in metastatic prostate cancer is prolongation of survival with good quality of life . Quality of life (health-related) is often used as an endpoint parameter in phase III trials in metastatic prostate cancer, but the value of using HRQOL in this context has not been assessed to date.
In order to evaluate the role of HRQOL assessment in contemporary phase III trials in prostate cancer, we searched the PubMed database to identify publications presenting the results of these trials on systemic therapies for prostate cancer published between January 2000 and December 2015. The analysis was separately presented in ten leading journals. We searched for companion papers reporting on QOL separately.
We identified 84 studies which included a total of 57,193 patients in ten leading journals and 27 studies (7270 patients) in other journals. HRQOL parameters were described or mentioned in the main publication in 25 publications and four companions in total. There was no obvious trend in quality of life reported over two 8-year periods . The explicit statistical comparisons were reported in 22/25 cases (88 %), with significant difference in only 10/25 (40 %) studies and in eight cases (80 %) was conducive to the examined arm. There was no significant association between improvements in HRQOL and improvements in overall survival (OS) or any other primary endpoint in the analyzed studies. Only one study was found which presented the difference in quality of life with no difference in the primary endpoint.
HRQOL is an indicator of benefit during treatment of patients with metastatic prostate cancer, but it is unlikely that HRQOL results can help clinicians choose between treatments given that they are not correlated with changes in OS or at other primary endpoints.
KeywordsProstate cancer Chemotherapy Hormonal therapy Treatment results Quality of life
Compliance with ethical standards
Conflict of interests
The author declares no conflict of interest.
- 1.Mould, R. (2008). Cancer statistics overview with special reference to prostate, colon and rectum, lung, breast and cervix uteri. Nowotwory Journal of Oncology, 58, 213–220.Google Scholar
- 2.Wojciechowska, U., Didkowska, J., & Zatoński, W. (2012). Nowotwory złośliwe w Polsce. Warszawa: Centrum Onkologii Instytut.Google Scholar
- 3.American Cancer Society. (2004). Cancer facts and figures-2004 Atlanta. Atlanta: American Cancer Society.Google Scholar
- 11.Loriot, Y., Miller, K., Sternberg, C. N., et al. (2015). Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncology, 16, 509–521.CrossRefPubMedGoogle Scholar
- 12.Basch, E., Autio, K., Ryan, C. J., et al. (2013). Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, 14, 1193–1199.CrossRefPubMedGoogle Scholar
- 13.Fosså, S. D., Slee, P. H., Brausi, M., et al. (2001). Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. Journal of Clinical Oncology, 19, 62–71.CrossRefPubMedGoogle Scholar
- 15.Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015). Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology, 26, 179–185.CrossRefPubMedGoogle Scholar
- 18.Shamash, J., Powles, T., Sarker, S. J., et al. (2011). A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred Diethylstilbestrol. British Journal of Cancer, 104, 620–628.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Small, E. J., Meyer, M., Marshall, M. E., et al. (2000). Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. Journal of Clinical Oncology, 18, 1440–1450.CrossRefPubMedGoogle Scholar
- 23.Brundage, M., Sydes, M. R., Parulekar, W. R., et al. (2015). Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. Journal of Clinical Oncology, 33, 2151–2157.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Ernst, D. S., Tannock, I. F., Winquist, E. W., et al. (2003). Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology, 21, 3335–3342.CrossRefPubMedGoogle Scholar
- 25.Saad, F., Gleason, D. M., Murray, R., et al. (2002). Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.CrossRefPubMedGoogle Scholar
- 26.Fransson, P., Lund, J. A., Damber, J. E., et al. (2009). Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncology, 10, 370–380.CrossRefPubMedGoogle Scholar
- 27.Denham, J. W., Wilcox, C., Joseph, D., et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, 13, 1260–1270.CrossRefPubMedGoogle Scholar
- 34.King, M., Bell, M. L., Costa, D., Butow, P., & Oh, B. (2014). The quality of life questionnaire core 30 (QLQ-C30) and functional assessment of cancer-general (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. Journal of Clinical Epidemiology, 67, 100–107.CrossRefPubMedGoogle Scholar
- 39.Dancey, J., Zee, B., Osoba, D., et al. (1997). Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Quality of Life Research, 6, 151–158.CrossRefPubMedGoogle Scholar